Skip to content

Electroacupuncture improves the clinical efficacy evaluation of obese patients with prediabetes

Electroacupuncture improves the clinical efficacy evaluation of obese patients with prediabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002488
Enrollment
Unknown
Registered
2025-12-24
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes with obesity

Interventions

Electroacupuncture:electroacupuncture,The patient lies on his back, the whole body is relaxed, routinely disinfected, and the abdominal acupuncture points are punctured directly by f0.30mm×50mm or f0.
Sham electroacupuncture:Sham electroacupuncture,Acupuncture points The acupuncture points

Sponsors

The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria of obesity and prediabetes at the same time; (2) Age 18-64 years old; (3) Be able to correctly describe their wishes, voluntarily fill in the informed consent form, and agree to participate in clinical trials. Note: The above three items must be met at the same time.

Exclusion criteria

Exclusion criteria: (1) Secondary obesity caused by hypothyroidism, Cushing's syndrome, hyperadrenocorticism, polycystic ovary syndrome, etc.; (2) Suffering from hyperthyroidism, endocrine tumors, and extensive liver damage resulting in impaired glucose regulation; (3) Drugs that have a significant impact on body weight or blood sugar in the past 3 months: hormonal drugs (glucocorticoids (such as dexamethasone, hydrocortisone, prednisone, methylprednisone, etc., sex hormones, growth hormone, etc.), antipsychotics, antidepressants, antiseizure drugs, hormonal contraceptives;

Design outcomes

Primary

MeasureTime frame
The percentage change in the subject's weight from baseline at the end of the 8th week of treatment;

Secondary

MeasureTime frame
Percent change in subject's weight from baseline;Percentage of patients who lost more than 5% of their body weight from baseline;Percentage of patients who lost more than 7% of their body weight from baseline;Change from baseline in fasting blood glucose (FPG), blood glucose value (2hPG) after 2 hours, glycated hemoglobin (HbA1c) and percentage of patients who returned to normal values;Changes in body mass index (BMI), waist circumference, waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), and blood pressure (BP) from baseline;The change value of appetite VAS score from baseline;Changes from baseline in fasting blood insulin (FINS), insulin after 2 hours, fasting C-peptide, C-peptide after 2 hours, insulin resistance index (HOMA-IR), and pancreatic islet ß cell function (HOMA-ß).;Total cholesterol (TC), trisglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol Changes from baseline in alcohol (HDL-C), blood uric acid (UA), c-reactive protein, leptin, adiponectin, and fatty acids;The change from baseline in the score of the European Five-Dimensional Health Scale (EQ-5D-5L).;The change of PHQ-4 score from baseline;Proportion of progression to diabetes at one year of enrollment;Baseline expectancy evaluation, acupuncture trust evaluation, acupuncture blinding effect evaluation, adherence evaluation, Diet and exercise evaluation;

Countries

China

Contacts

Public ContactZHANG WEI

The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

1633864674@qq.com13789031977

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026